Shares of Tiziana Life Sciences surged 15% to $0.77 in pre-market trading after the company reported that its nasal spray drug for a hard-to-treat form of multiple sclerosis hit key goals in an early-stage trial. But the data came with significant caveats, and the company faces a cash crisis that could force dilutive fundraising within months.
The Lower Dose Worked, the Higher Dose Didn't — and That's a Problem. The randomized, placebo-controlled trial met its dual primary endpoints: the 50-microgram dose showed a statistically significant reduction in brain inflammation (p=0.0168) after 12 weeks compared to placebo. But the higher 100-microgram dose did not show a significant difference on the imaging measure, and disability scores did not change during treatment. In drug development, a clear dose-response relationship — where a higher dose produces a stronger effect — is typically what regulators want to see. The absence of that pattern here complicates the path to a larger, pivotal trial.
A Huge Unmet Need, But Years Away from Any Revenue. The trial targets patients with non-active secondary progressive MS, "a population with significant unmet need and limited treatment options."
The SPMS drug market accounted for roughly $6.3 billion in 2025 and is projected to reach $13.4 billion by 2035. That's a massive opportunity, but Tiziana is still in Phase 2a — the earliest stage of efficacy testing. One pipeline analytics platform estimates foralumab's probability of eventual approval at just 17%.
The Cash Runway Is Dangerously Short. As of December 31, 2025, Tiziana had just $4.0 million in cash with a working capital deficit of $2.7 million.
It raised $8.6 million in January 2026, but auditors still flagged a going concern warning.
Management's own forecast indicates current cash "will be utilised during H2 2026 without additional financing." With the stock now at $0.77, any new equity raise would heavily dilute existing shareholders.
The Stock Is Still Down Sharply Despite the Pop. Even after today's jump, TLSA trades roughly 19% below its $0.95 close just last week and about 60% off its 52-week high. One analysis pegged Tiziana's cash backing at just 2.8% of market cap — meaning virtually the entire stock price is a bet on this one drug. The trial produced encouraging but incomplete evidence. Investors now wait for FDA discussions that will determine whether this data is enough to design a larger study — all while the cash clock ticks.